Hexavac diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis, hepatitis B (recombinant) and Haemophilus influenzae type b conjugate vaccine, adjuvanted
- Purified adsorbed diptheria toxoid (PDT)
- Purified tetanus toxoid (PTT)
- Purified pertussis toxoid (PTxT)
- Purified pertussis filamentous haemagglutinin (FHA)
- Hepatitis B S surface antigen recombinant (HBsAG)
- Inactivated poliovirus (IPV):
- type 1 (Mahoney)
- type 2 (MEF 1)
- type 3 (Saukett)
- Haemophilus influenzae type b polysaccharide, conjugated to tetanus protein (PRP-T)
Pharmaco-therapeutic group (ATC Code):
- Bacterial and viral vaccines, combined (J07CA)
Currently approved therapeutic indication(s):
- This combined vaccine is indicated for primary and booster vaccination of children against diphtheria, tetanus, pertussis, hepatitis B caused by all known subtypes of viruses, poliomyelitis and invasive infections caused by Haemophilus influenzae type b.
Marketing Authorisation Holder:
- AVENTIS PASTEUR MSD, SNC 8, rue Jonas Salk F-69007 Lyon France
Date of issue of Marketing Authorisation valid throughout the European Union:
- 23 October 2000
Orphan medicinal product designation date:
- Not applicable
Hexavac is a hexavalent vaccine which contains combined antigens derived from Corynebacterium diphtheriae, Clostridium tetani, Bordetella pertussis, hepatitis B virus, polio virus and Haemophilus influenzae type b. It is developed for primary and booster vaccination of children against the viruses and bacteria mentioned above.
The approval was based on results from clinical trials, which investigated the immunogenicity and reactogenicity of Hexavac when administered according to specific primary and booster vaccination schedules. These studies showed the protective efficacy of Hexavac against the above diseases in infants.
The most common adverse events were transient local reactions (pain, redness, swelling at the injection site) and systemic reactions (loss of appetite, fever, drowsiness, irritability).
The following adverse effects were reported very rarely: allergic reaction, chills, fatigue, hypotonichyporesponsive episode, malaise, oedema, pallor, swelling or oedema of the entire limb(s), transient local lymph node swelling, convulsions (febrile and non febrile), encephalitis, encephalopathy with acute brain oedema, eyes rolling, Guillain Barré Syndrome, hypotonia, neuritis, abdominal pain, meteorism, nausea, petechiae, purpura, purpura thrombocytopenic, thrombocytopenia, agitation, sleep disorder, dyspnoea or Stridor inspiratory, angioedema, erythema, pruritus, rash, urticaria and flushing.
The CHMP, on the basis of quality, efficacy and safety data submitted, consideres that the overall benefit /risk ratio for Hexavac remains favourable in the approved indication.
For detailed conditions for the use of this product, scientific information or procedural aspects please refer to the relevant modules.
European Medicines Agency
This document is a summary of the European public assessment report (EPAR) for Hexavac. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Hexavac.
The full EPAR for Hexavac can be found in:
For more information about treatment with Hexavac, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
This summary was last updated in 10-2005.